Individualized tumor-reactive T cells exhibit a potent anti-tumor response in prostate cancer
In this study, we developed a protocol for the generation of tumor-responsive T cells based on autologous tumor antigens in patients with prostate cancer. This platform is characterized by its multitargeted, individualized, affordability, and minimal adverse effects, holding significant promise in the treatment of prostate cancer as well as other solid tumors.
Authors
- Houbao Huang (ORCID: https://orcid.org/0000-0001-8291-0507)
- Xueyi Qian (ORCID: https://orcid.org/0000-0003-2167-8278)
- Nanlin Jiao
- Zhenyu Xu (ORCID: https://orcid.org/0000-0002-7089-6880)
- Lianjun He
- Zhuo Dong (ORCID: https://orcid.org/0000-0002-9211-1431)
- Huimin Shao
- Lei Tang (ORCID: https://orcid.org/0009-0008-6526-5807)
- Zhen Han (ORCID: https://orcid.org/0000-0002-9547-9063)
- Xing Bao
- Weijie He (ORCID: https://orcid.org/0009-0007-6382-5738)
- Yao Wu (ORCID: https://orcid.org/0000-0003-4172-6994)
Institutions
- Wannan Medical College (CN)
- First Affiliated Hospital of Wannan Medical College (CN)
Publication Details
- Journal
- Translational Oncology
- Published
- 2025-02-21
- DOI
- https://doi.org/10.1016/j.tranon.2025.102322
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00